[1] Kumar R, Lim J, Mekary RA, et al.Traumatic spinal injury: global epidemiology and worldwide volume[J]. World Neurosurg, 2018, 113: e345-e363.
[2] Passuni D, Dalzotto E, F Gath C, et al. Reliability of the Spanish version of the Wheelchair Skills Test 4.2 for manual wheelchair users with spinal cord injury [J]. Disabil Rehabil Assist Technol, 2018-05-03: 1-4. doi: 10.1080/17483107.2018.1463404.[Epub ahead of print]
[3] Doble A.The pharmacology and mechanism of action of riluzole[J]. Neurology, 1996, 47(6 Suppl 4): S233-S241.
[4] Favero FM, Voos MC, Castro I, et al.Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS[J]. Arq Neuropsiquiatr, 2017, 75(8): 515-522.
[5] Tator CH, Hashimoto R, Raich A, et al.Translational potential of preclinical trials of neuroprotection through pharmacotherapy for spinal cord injury[J]. J Neurosurg Spine, 2012, 17(1 Suppl): 157-229.
[6] Martins BC, Torres B, de Oliveira KM, et al. Association of riluzole and dantrolene improves significant recovery after acute spinal cord injury in rats[J]. Spine J, 2018, 18(3): 532-539.
[7] Lamanauskas N, Nistri A.Riluzole blocks persistent Na<sup>+</sup> and Ca<sup>2+</sup> currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro[J]. Eur J Neurosci, 2008, 27(10): 2501-2514.
[8] Caglar YS, Demirel A, Dogan I, et al. Effect of riluzole on spinal cord regeneration with hemisection method before injury [J]. World Neurosurg, 2018-05-10. pii: S1878-8750(18)30444-3. doi: 10.1016/j.wneu.2018.02.171.[Epub ahead of print].
[9] Schwartz G, Fehlings MG.Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole[J]. Prog Brain Res, 2002, 137: 177-190.
[10] Ulndreaj A, Badner A, Fehlings MG.Promising neuroprotective strategies for traumatic spinal cord injury with a focus on the differential effects among anatomical levels of injury[J]. F1000Res, 2017, 6: 1907.
[11] Fehlings MG, Nakashima H, Nagoshi N, et al.Rationale, design and critical end points for the Riluzole in Acute Spinal Cord Injury Study (RISCIS): a randomized, double-blinded, placebo-controlled parallel multi-center trial[J]. Spinal Cord, 2016, 54(1): 8-15.
[12] Xie RG, Zheng DW, Xing JL, et al.Blockade of persistent sodium currents contributes to the riluzole-induced inhibition of spontaneous activity and oscillations in injured DRG neurons[J]. PLoS One, 2011, 6(4): e18681.
[13] Wu Y, Satkunendrarajah K, Fehlings MG.Riluzole improves outcome following ischemia-reperfusion injury to the spinal cord by preventing delayed paraplegia[J]. Neuroscience, 2014, 265: 302-312.
[14] Heurteaux C, Laigle C, Blondeau N, et al.Alpha-linolenic acid and riluzole treatment confer cerebral protection and improve survival after focal brain ischemia[J]. Neuroscience, 2006, 137(1): 241-251.
[15] Brennan BP, Hudson JI, Jensen JE, et al.Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole[J]. Neuropsychopharmacology, 2010, 35(3): 834-846.
[16] Chen C, Chen H, Xu C, et al.Role of interleukin-1beta in hypoxia-induced depression of glutamate uptake in retinal Muller cells[J]. Graefes Arch Clin Exp Ophthalmol, 2014, 252(1): 51-58.
[17] Diao L, Hellier JL, Uskert-Newsom J, et al.Diphenytoin, riluzole and lidocaine: three sodium channel blockers, with different mechanisms of action, decrease hippocampal epileptiform activity[J]. Neuropharmacology, 2013, 73: 48-55.
[18] Abdallah CG, Coplan JD, Jackowski A, et al.A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD[J]. Eur Neuropsychopharmacol, 2013, 23(4): 276-284.
[19] Tator CH.Update on the pathophysiology and pathology of acute spinal cord injury[J]. Brain Pathol, 1995, 5(4): 407-413.
[20] Sadowsky C, Volshteyn O, Schultz L, et al.Spinal cord injury[J]. Disabil Rehabil, 2002, 24(13): 680-687.
[21] Tashiro S, Nakamura M, Okano H.The prospects of regenerative medicine combined with rehabilitative approaches for chronic spinal cord injury animal models[J]. Neural Regen Res, 2017, 12(1): 43-46.
[22] Norenberg MD, Smith J, Marcillo A.The pathology of human spinal cord injury: defining the problems[J]. J Neurotrauma, 2004, 21(4): 429-440.
[23] Siddiqui AM, Khazaei M, Fehlings MG.Translating mechanisms of neuroprotection, regeneration, and repair to treatment of spinal cord injury[J]. Prog Brain Res, 2015, 218: 15-54.
[24] Wagner FJ, Stewart WB.Effect of trauma dose on spinal cord edema[J]. J Neurosurg, 1981, 54(6): 802-806.
[25] Dasari VR, Veeravalli KK, Dinh DH.Mesenchymal stem cells in the treatment of spinal cord injuries: A review[J]. World J Stem Cells, 2014, 6(2): 120-133.
[26] Agrawal SK, Fehlings MG.Mechanisms of secondary injury to spinal cord axons in vitro: role of Na<sup>+</sup>, Na(+)-K(+)-ATPase, the Na(+)-H<sup>+</sup> exchanger, and the Na(+)-Ca<sup>2+</sup> exchanger[J]. J Neurosci, 1996, 16(2): 545-552.
[27] Stys PK, Sontheimer H, Ransom BR, et al.Noninactivating, tetrodotoxin-sensitive Na<sup>+</sup> conductance in rat optic nerve axons[J]. Proc Natl Acad Sci U S A, 1993, 90(15): 6976-6980.
[28] Stys PK.General mechanisms of axonal damage and its prevention[J]. J Neurol Sci, 2005, 233(1-2): 3-13.
[29] Kwon BK, Stammers AM, Belanger LM, et al.Cerebrospinal fluid inflammatory cytokines and biomarkers of injury severity in acute human spinal cord injury[J]. J Neurotrauma, 2010, 27(4): 669-682.
[30] Coderre TJ, Kumar N, Lefebvre CD, et al.A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain[J]. J Neurochem, 2007, 100(5): 1289-1299.
[31] Carbone M, Duty S, Rattray M.Riluzole elevates GLT-1 activity and levels in striatal astrocytes[J]. Neurochem Int, 2012, 60(1): 31-38.
[32] Mizuta I, Ohta M, Ohta K, et al.Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes[J]. Neurosci Lett, 2001, 310(2-3): 117-120.
[33] Caumont AS, Octave JN, Hermans E.Specific regulation of rat glial cell line-derived neurotrophic factor gene expression by riluzole in C6 glioma cells[J]. J Neurochem, 2006, 97(1): 128-139.
[34] Karadimas SK, Laliberte AM, Tetreault L, et al.Riluzole blocks perioperative ischemia-reperfusion injury and enhances postdecompression outcomes in cervical spondylotic myelopathy[J]. Sci Transl Med, 2015, 7(316): 194r-316r.
[35] Wu Y, Satkunendrarajah K, Teng Y, et al.Delayed post-injury administration of riluzole is neuroprotective in a preclinical rodent model of cervical spinal cord injury[J]. J Neurotrauma, 2013, 30(6): 441-452.
[36] Satkunendrarajah K, Nassiri F, Karadimas SK, et al.Riluzole promotes motor and respiratory recovery associated with enhanced neuronal survival and function following high cervical spinal hemisection[J]. Experimental Neurology, 2016, 276: 59-71.
[37] Fehlings MG, Wilson JR, Frankowski RF, et al.Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial[J]. J Neurosurg Spine, 2012, 17(1 Suppl): 151-156.
